Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:MTSR News 10 November 2025 - 21 November 2025

Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Pfizer has closed its up to $10 billion acquisition of Metsera (MTSR) and raised $6 billion in bonds to help fund the deal. Here’s what today’s developments mean for former Metsera shareholders, Pfizer investors and the future of the obesity drug market. What Happened Today: Pfizer Locks In $6 Billion Bond Financing The main fresh headline for 21 November 2025 is on the financing side, not on Metsera’s standalone stock — because MTSR no longer trades. German market outlet boerse‑global/ad‑hoc‑news reports that Pfizer has successfully raised $6 billion in the U.S. investment‑grade bond market to support the cash portion of
21 November 2025
···
Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Metsera Inc. (NASDAQ: MTSR) stops trading today, November 14, 2025, as Pfizer closes its up to $10 billion obesity-drug acquisition. Here’s what Metsera shareholders and obesity-market investors need to know about the deal terms, CVR, delisting, and future milestones. Date: November 14, 2025Ticker: MTSR (Metsera, Inc.) – now being delisted On Friday, November 14, 2025, Metsera, Inc. officially disappears from the Nasdaq tape. Trading in Metsera (NASDAQ: MTSR) has been suspended after Pfizer completed its acquisition of the obesity-focused biotech in a deal valued at up to $10 billion, capping one of the fiercest pharma bidding wars of the year.
14 November 2025
···
Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

Published: November 10, 2025 Key takeaways Market snapshot: AI leads early rebound U.S. index futures moved higher Monday as Senate action over the weekend boosted hopes for a stopgap funding bill to end the record federal shutdown. Nasdaq 100 futures led gains and AI bellwether Nvidia (NASDAQ: NVDA) traded about 3% higher premarket, pacing a broader chip bounce. Reuters Adding to the tone, Nvidia CEO Jensen Huang said over the weekend that demand for the company’s next‑gen Blackwell platform remains “very strong,” underscoring continued wafer needs from TSMC. The remarks come as investors look to AI hardware leaders to reassert
10 November 2025
····

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop